Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma
2016 ASCO Annual MeetingAnthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).
Related Videos
Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death
Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether p...
Helen MacKay, MD, and Ursula A. Matulonis, MD, on Epithelial Ovarian Cancer: Results From the OV21-PETROC Trial
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, and Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discuss findings from this phase ...
James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients
James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings ...
